Stockscreener 앱 받기
134.66
0.58%
0.77
시간 외 거래:
134.66
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Is Neurocrine Biosciences (NBIX) Offering Value After Recent Share Price Weakness - Yahoo Finance
Does Neurocrine Biosciences (NBIX) Price Weakness Signal A Long Term Opportunity? - simplywall.st
Assessing Neurocrine Biosciences (NBIX) Valuation After New Phase 2 VMAT2 Tardive Dyskinesia Trial Launch - Yahoo Finance
Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules - NeurologyLive
Neurocrine initiates phase 2 study for tardive dyskinesia treatment By Investing.com - Investing.com Nigeria
Neurocrine Biosciences begins Phase II NBI-1065890 trial for TD - Clinical Trials Arena
Gainers Report: What is Neurocrine Biosciences Inc.’s TAM (Total Addressable Market)2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - marketscreener.com
Neurocrine initiates phase 2 study for tardive dyskinesia treatment - Investing.com
Neurocrine Biosciences, Inc. $NBIX Holdings Lifted by Wealth Enhancement Advisory Services LLC - MarketBeat
Neurocrine tests potential longer-acting tardive dyskinesia treatment - Stock Titan
New INGREZZA VMAT2 Data vs AUSTEDO XR Might Change The Case For Investing In Neurocrine (NBIX) - simplywall.st
Volume Report: How cyclical is Neurocrine Biosciences Incs revenue stream2025 Volume Leaders & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
(NBIX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Assessing Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Clinical Data And Pipeline Updates - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $178.00 at UBS Group - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $178 - 富途牛牛
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock - Chartmill
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Recap Report: Why is Neurocrine Biosciences Inc stock going up2025 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - The AI Journal
Neurocrine sets Feb. 11 webcast for Q4 and 2025 year-end financial results - Stock Titan
Aug Analyst Calls: Is Momentus Inc Equity Warrant a momentum stockQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Rakuten Investment Management Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 36,400 Shares - MarketBeat
Seizert Capital Partners LLC Invests $9.83 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Aug Wrap: What hedge funds are buying Neurocrine Biosciences IncJuly 2025 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
Stock Market Recap: Is Neurocrine Biosciences Inc a turnaround storyQuarterly Performance Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Neurocrine Biosciences officer sells $168,849 in stock - MSN
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 21,900 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Position Reduced by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Campbell & CO Investment Adviser LLC Acquires Shares of 16,470 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) INGREZZA’s VMAT2 Edge Over AUSTEDO XR - simplywall.st
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Head To Head Clinical Data - simplywall.st
Neurocrine presents data showing INGREZZA achieved higher target occupancy - StreetInsider
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - wvnews.com
Neurocrine Biosciences describes new GLP-1R/GIPR/GCGR agonists - BioWorld MedTech
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by SG Americas Securities LLC - MarketBeat
Brain scan study finds INGREZZA hits key movement target twice as hard - Stock Titan
With Neurocrine Biosciences, Inc. (NASDAQ:NBIX) It Looks Like You'll Get What You Pay For - 富途资讯
Major Decision: Darin Lippoldt Exercises Options, Realizing $320K At Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Gap Down: Can Neurocrine Biosciences Inc be recession proofBreakout Watch & Verified Momentum Watchlists - baoquankhu1.vn
Price-Driven Insight from (NBIX) for Rule-Based Strategy - Stock Traders Daily
Investor Mood: What is the Moat Score of Harbor Etf Trust Smid Capital Value EtfWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Lobbying Update: $60,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Neurocrine Biosciences CEO sells $235,577 in stock - MSN
Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Peregrine Capital Management LLC Reduces Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Is Neurocrine Biosciences (NBIX) Pricing Reflect Long Term Cash Flow Potential After Recent Weakness - simplywall.st
2.03%
0.75%
자본화:
|
볼륨(24시간):